[1]孙建国,李梦侠,杨镇洲.PD-L1高表达晚期非小细胞肺癌一线免疫治疗策略的探讨[J].第三军医大学学报,2020,42(03):314-320.
点击复制

PD-L1高表达晚期非小细胞肺癌一线免疫治疗策略的探讨(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
42卷
期数:
2020年第03期
页码:
314-320
栏目:
学术沙龙
出版日期:
2020-02-15

文章信息/Info

作者:
孙建国李梦侠杨镇洲
陆军军医大学(第三军医大学)第二附属医院肿瘤科;陆军军医大学(第三军医大学)大坪医院肿瘤科;重庆医科大学第二附属医院肿瘤科
文献标志码:
A

参考文献/References:

[1]PILOTTO S, CARBOGNIN L, ROSSI A, et al. Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?[J]. Semin Oncol, 2018, 45(3): 176-180. DOI:10.1053/j.seminoncol.2018.08.002. 
[2]ZEHIR A, BENAYED R, SHAH R H, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10, 000 patients[J]. Nat Med, 2017, 23(6): 703-713. DOI:10.1038/nm.4333.
[3]RECK M, RODRGUEZ-ABREU D, ROBINSON A G, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016, 375(19): 1823-1833. DOI:10.1056/NEJMoa1606774. 
[4]WU Y L, ZHANG L, FAN Y, et al. KEYNOTE-042 China study: first-line pembrolizumab vs chemotherapy in Chinese patients with advanced NSCLC with PD-L1 TPS ≥1%[J]. J Thorac Oncol, 2019, 14(10): S290-S291. DOI:10.1016/j.jtho.2019.08.584. 
[5]MOK T S K, WU Y L, KUDABA I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019 (393): 1819-1830. DOI:10.1016/S0140-6736(18)32409-7.
[6]CARBONE D P, RECK M, PAZ-ARES L, et al. First-line nivolumab in stage Ⅳ or recurrent non-small-cell lung cancer[J]. N Engl J Med, 2017, 376(25): 2415-2426. DOI:10.1056/NEJMoa1613493. 
[7]SPIGEL D R, DE MARINIS F, GIACCONE G, et al. IMpower110: Interim OS Analysis of a Phase Ⅲ Study of Atezolizumab (atezo) vs Platinum-Based Chemotherapy (chemo) as 1L Treatment (tx) in PD-L1-selected NSCLC[C]. 2019 European Society for Medical Oncology.[2019-09-27].https://bit.ly/2lxRNHQ. 
[8]GARASSINO M C. Immue-check point inhibitors(ICI) in non-oncogenic addicted mNSCLC[C]. 2019 European Society for Medical Oncology.[2019-11-22]. https://oncologypro.esmo.org/Meeting-Resources/ESMO-Asia-Congress-2019/Immune-Check-Points-Inhibitors-ICI-in-non-oncogenic-addicted-mNSCLC.
[9]GANDHI L, RODRGUEZ-ABREU D, GADGEEL S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22): 2078-2092. DOI:10.1056/NEJMoa1801005.
[10]SOCINSKI M A, JOTTE R M, CAPPUZZO F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J]. N Engl J Med, 2018, 378(24): 2288-2301. DOI:10.1056/nejmoa1716948.
[11]PAZ-ARES L, LUFT A, VICENTE D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21): 2040-2051. DOI:10.1056/NEJMoa1810865.
[12]ZHOU Y X, LIN Z, ZHANG X Y, et al. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy[J]. J Immunother Cancer, 2019, 7(1): 120. DOI:10.1186/s40425-019-0600-6.
[13]LANGER C J, GADGEEL S M, BORGHAEI H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study[J]. Lancet Oncol, 2016, 17(11): 1497-1508. DOI:10.1016/S1470-2045(16)30498-3.
[14]ZEHIR A, BENAYED R, SHAH R H, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10, 000 patients[J]. Nat Med, 2017, 23(6): 703-713. DOI:10.1038/nm.4333.
[15]RECK M, SCHENKER M, LEE K H, et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase Ⅲ CheckMate 227 trial[J]. Eur J Cancer, 2019, 116: 137-147. DOI:10.1016/j.ejca.2019.05.008.
[16]DONG Z Y, ZHONG W Z, ZHANG X C, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma[J]. Clin Cancer Res, 2017, 23(12): 3012-3024. DOI:10.1158/1078-0432.CCR-16-2554.
封[17]RIZZO M, ABATE N, CHANDALIA M, et al. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study[J]. J Clin Endocrinol Metab, 2015, 100(2): 603-606. DOI:10.1210/jc.2014-2291. 
[18]JOTTE R, CAPPUZZO F, VYNNYCHENKO I, et al. IMpower131: final OS results of carboplatin + nab-paclitaxel ± atezolizumab in advanced squamous NSCLC[C].  2019 World Conference on Lung Cancer. [2019-9-10]. http://bit.ly/2zivx85. 
[19]WANG Z J, ZHAO J, WANG G Q, et al. Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade[J]. Cancer Res, 2018, 78(22): 6486-6496. DOI:10.1158/0008-5472.CAN-18-1814.
[20]CONFORTI F, PALA L, BAGNARDI V, et al. Sex-based heterogeneity in response to lung cancer immunotherapy: A systematic review and meta-analysis[J].  J Natl Cancer Inst, 2019, 111(8): 772-781. DOI:10.1093/jnci/djz094.
[21]WEST H, MCCLEOD M, HUSSEIN M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(7): 924-937. DOI:10.1016/S1470-2045(19)30167-6.
[22]CRISTESCU R, MOGG R, AYERS M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy[J]. Science, 2018, 362(6411): eaar3593. DOI:10.1126/science.aar3593.

更新日期/Last Update: 2020-02-06